<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271462</url>
  </required_header>
  <id_info>
    <org_study_id>W20_025 # 20.051</org_study_id>
    <nct_id>NCT04271462</nct_id>
  </id_info>
  <brief_title>The Influence of Two Different CO2 Absorbers on Sevoflurane Consumption During Anaesthesia</brief_title>
  <official_title>The Influence of Two Different CO2 Absorbers on Sevoflurane Consumption During Anaesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditional sodalime CO2 absorbers are known to not only react with CO2 but also with
      sevoflurane. Therewith, a potentially harmful compound (compound A) is formed that can be
      nephrotoxic. In the United States, the sevoflurane manufacturer therefore recommends keeping
      the FGF (FGF) at &gt;2.0 L min-1 if a sodalime CO2 absorbent is used. Amsorb Plus® (Datex-Ohmeda
      Inc., Madison, WI, USA), is a novel type of CO2 absorbent that does not react with
      sevoflurane. This allows the FGF to be reduced to 0.5 L min-1. This has two important
      advantages: (i) less fresh sevoflurane is added to the circle system, and (ii) the
      sevoflurane that is in the system does not react with the CO2 absorber.

      Sevoflurane is a potent greenhouse gas with a 100 year CO2-equivalents of 120. Measures that
      can reduce the consumption of volatile anaesthetics could make a significant contribution to
      reducing the carbon footprint of the operative process. Additionally, Amsorb Plus® canisters
      seem to have a longer life span than sodalime canisters and do not need to be disposed of via
      toxic waste stream, but via domestic waste.

      In this study, we were interested if (i) the use of Amsorb Plus leads to a reduction in
      sevoflurane usage and therefore contribute to a reduction in the CO2 footprint of general
      anaesthesia with sevoflurane, (ii) Does the use of Amsorb Plus® lead to a reduction in the
      amount of (toxic) waste produced by operating theatres?

      Comparator: a traditional sodalime CO2 absorber (Medisorb™ Multi-Absorber Original,
      CareFusion, Helsinki, Finland).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Influence of CO2 filters on Sevoflurane consumption</measure>
    <time_frame>30 minutes per filter</time_frame>
    <description>Comparing Sevoflurane consumption between Amsorb Plus and sodalime CO2 absorbers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of fresh gas flow on Sevoflurane consumption</measure>
    <time_frame>30 minutes per fresh gas flow setting</time_frame>
    <description>Comparing Sevoflurane consumption between 0.5 and 2.0 liters per minute fresh gas flow</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Estimated CO2 footprint and environmental impact of general anaesthesia with two different CO2 filters</measure>
    <time_frame>30 minutes</time_frame>
    <description>Estimate the CO2 footprint and environmental impact of general anaesthesia with sevoflurane comparing two different CO2 filters using life cycle analysis methods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Estimated cost of general anaesthesia with two different CO2 filters</measure>
    <time_frame>30 minutes</time_frame>
    <description>Estimate the total cost of general anaesthesia with sevoflurane comparing two different CO2 filters using life cycle analysis methods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Estimated CO2 footprint and environmental impact of general anaesthesia with two fresh gas flow settings</measure>
    <time_frame>30 minutes</time_frame>
    <description>Estimate the CO2 footprint of general anaesthesia with sevoflurane comparing two different fresh gas flow settings using life cycle analysis methods.</description>
  </other_outcome>
  <other_outcome>
    <measure>Estimated cost of general anaesthesia with two fresh gas flow settings</measure>
    <time_frame>30 minutes</time_frame>
    <description>Estimate the total cost of general anaesthesia with sevoflurane comparing two different fresh gas flow settings.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>Patients undergoing surgery (&gt;120 min) with the use of sevoflurane based general anaesthesia (in 1.0 MAC concentration).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparing two CO2 absorbers in the ventilator circuit</intervention_name>
    <description>General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):
I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing general anesthesia with sevoflurane for &gt; 2 hours.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Adult patient

          -  non-pregnant

          -  ASA-I to ASA-III

          -  undergoing Sevoflurane based general anaesthesia (in a therapeutic concentration of
             1.0 MAC)

          -  Elective surgery

          -  Scheduled operating time &gt;2 hours.

        Exclusion Criteria:

          -  Unable/ unwilling to participate

          -  ASA-IV or higher

          -  Age &lt; 18 years

          -  Known pregnancy

          -  Contra-indications for sevoflurane anaesthesia

          -  Emergency surgery

          -  Scheduled operating time &lt;2 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Niek Sperna Weiland, MD PhD</last_name>
    <phone>020-5669111</phone>
    <email>N.H.SpernaWeiland@amsterdamumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amsterdam UMC, location AMC</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Hermanides, MD PhD</last_name>
      <phone>+31 20 5669111</phone>
      <email>j.hermanides@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Niek Sperna Weiland, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jante Sinnige, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Niek Sperna Weiland</investigator_full_name>
    <investigator_title>Staff Anaesthesiologist (MD PhD)</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

